On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

US stocks rose on Monday as investors reacted to progress toward ending the US government shutdown of 40 days. The S&P 500 ...

A man who fainted in the Oval Office last week was a patient of a weight-loss drug company, according to reports.

Pfizer is acquiring obesity drug developer Metsera for $10B, beating out Novo Nordisk after antitrust concerns led Novo to ...

Ever wondered if Novo Nordisk’s stock is a hidden bargain or already priced for perfection? Let’s break down what’s happening beneath the surface so you can invest with clarity. The stock has seen ...

Access to the obesity medications known as GLP-1 receptor agonists has been a consistent problem for patients because of ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.

This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths ...

NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand name Poviztra in India. This collaboration aims to expand ...

Pfizer wins a $10 billion deal for weight-loss drugmaker Metsera, ending its bidding war with Danish rival Novo Nordisk.